High-Concentration Monoclonal Antibody Formulations: Innovations for Viscosity Reduction and Stability Improvement

Abstract

High-concentration monoclonal antibody (mAb) formulations have become essential for subcutaneous (SC) administration, enabling patient-centric dosing and reducing healthcare burden. However, achieving concentrations above 100–150 mg/mL presents multifactorial challenges, including steep viscosity increases, reversible self-association, opalescence, aggregation, and chemical degradation pathways that complicate manufacturability, stability, and device compatibility. Molecular determinants of rheology—electrostatics, hydrophobic surface patches, aromatic/cation–π interactions, glycosylation, and structural architecture—are further modulated by excipients, solvent structuring, and crowding effects. Advances in biophysical screening (DLS/SLS, SV-AUC, microrheology), predictive analytics, and machine learning models now allow earlier identification of viscosity liabilities, though validation under device-relevant shear conditions remains critical. Mitigation strategies include solution conditioning, excipient innovation, protein engineering, and optimized processing/presentation formats, supported by risk-based controls for excipient degradation and container–closure interactions. Co-optimization of rheology with device mechanics has enabled successful marketed products, while recombinant human hyaluronidase PH20 (rHuPH20)-facilitated large-volume SC (LVSC) delivery expands dosing feasibility. Embedding these efforts within a Quality by Design (QbD) framework—linking QTPP to CQAs, CMAs, CPPs, and design space verification—ensures robust product development. Case studies of trastuzumab, rituximab, daratumumab, adalimumab, tocilizumab, and pertuzumab/trastuzumab illustrate how formulation and device innovation converge to deliver high-concentration SC biologics. Looking forward, integration of novel excipients, AI/ML-based developability tools, and advanced delivery systems will accelerate development, reduce iteration cycles, and support next-generation patient-friendly antibody therapies.